European Union. ACCENTIA shall have the right to sublicense the BDSI Licensed Technology in the European Union with the prior written approval of BDSI, which approval is not to be unreasonably withheld. Each sublicense granted by ACCENTIA pursuant to this Agreement shall be consistent the provisions of this Agreement. Prior to the grant of each sublicense hereunder, ACCENTIA shall provide BDSI a copy of the sublicense. ACCENTIA shall not grant any paid-up license or accept equity in consideration, directly or indirectly, for such sublicenses without BDSI’s written approval.
Appears in 4 contracts
Samples: License Agreement (Biodelivery Sciences International Inc), License Agreement (Accentia Biopharmaceuticals Inc), License Agreement (Accentia Biopharmaceuticals Inc)